Edinburgh CDMO RoslinCT Wins up to $9.59 Million Scottish Enterprise Grant for Digital Manufacturing Push

RoslinCT, a cell therapy contract development and manufacturing organization headquartered in Edinburgh, has received a Research & Development grant of up to USD 9.59 million from Scottish Enterprise, the agency announced on 6 October 2026.

The money will fund a multi-year digital expansion plan intended to deepen the company's integrated digital and AI capabilities across its Scottish manufacturing operations.

Funding Targets Enhanced Digital Manufacturing Environment for Cell Therapies

According to the company, the programme will establish a digitally integrated manufacturing environment designed to improve operational efficiency, data connectivity, and manufacturing excellence.

A more connected and data-driven setup, RoslinCT says, will allow it to support clients throughout the product lifecycle and help bring innovative cell therapies to patients faster and at a lower cost.

Digital Tools Take on Growing Advanced Therapy Demand

The award arrives as digital technologies become increasingly central to delivering robust, scalable and efficient manufacturing processes for advanced therapies, a field where demand for treatments continues to rise.

RoslinCT's investment is intended to build a more connected manufacturing ecosystem supporting the development and production of cell therapies, while also generating high-value employment in Scotland.

The programme sits within the company's long-term strategy of investing in advanced manufacturing technologies and creating a highly connected, digitally enabled environment able to serve both clinical and commercial cell therapy production.

RoslinCT states the project is expected to contribute significantly to Scotland's life sciences sector through job creation and long-term economic growth.

Chief Executive Points to Efficiency and Quality Gains

Peter Coleman, Chief Executive Officer of RoslinCT, described the Scottish Enterprise support as an important investment in the future of advanced therapy manufacturing in Scotland.

"Digital technologies are transforming how cell therapies are developed and manufactured, enabling greater efficiency, consistency, and scalability while maintaining the highest quality standards," Coleman said.

"At RoslinCT, we are committed to building world-class manufacturing capabilities that help our clients bring innovative therapies to patients faster. This programme will strengthen our digital infrastructure, support continued innovation, and reinforce Scotland's position as a leading destination for cell and gene therapy manufacturing."

Scottish Enterprise Chief Executive Adrian Gillespie framed the grant as an example of the agency's role in enabling innovation at scale.

Noting that Scotland's life sciences sector has built a strong international reputation for innovation and expertise, Gillespie said, "RoslinCT's ambitious digital programme demonstrates their continued leadership in this field. This R&D project is a prime example of how Scottish Enterprise support can enable innovation at scale and strengthen competitiveness in global markets."

Government Minister Hails a Two-Decade Scottish Success Story

Tom Arthur, the Scottish Government's Minister for Business & Fair Work, called the grant good news for Edinburgh, for Scotland's life sciences sector and for work improving and saving lives worldwide.

Arthur observed that over the last twenty years RoslinCT has established itself as a Scottish success story, delivering and manufacturing life-changing therapies for cancer, genetic disorders, and other complex medical conditions.

"The Scottish Government and our enterprise agencies recognise the importance of helping our life sciences sector remain internationally competitive and will continue supporting and investing in our fantastic, world-renowned innovation," the Minister said.

From Dolly the Sheep Heritage to Two-Site Global Operations

The company behind the programme operates 22 purpose-built cGMP cell therapy suites across two sites, in Edinburgh, Scotland, and Hopkinton, Massachusetts.

Its services span process and analytical development, clinical and commercial manufacturing for both autologous and allogeneic cell therapies, iPSC cell line development, and gene editing and differentiation services. RoslinCT was founded in 2005 on the scientific heritage of the Roslin Institute, the home of the cloning of Dolly the Sheep.

The company has advanced cell-based medicines from early development through commercialization, with commercial product manufacture taking place at both of its sites, and it is a GHO Capital portfolio company. It continues to invest in expanding capabilities across process development, analytical development, GMP manufacturing, and commercial readiness to help cell therapy developers accelerate delivery of treatments to patients worldwide.

The Agency Behind the Award

Scottish Enterprise, which issued the grant, is Scotland's national economic development agency and a non-departmental public body of the Scottish Government.

It supports businesses to innovate and scale in order to transform the Scottish economy, focusing on new market opportunities through targeted investment, innovation, and internationalisation.

What the USD 9.59 Million Pledge Signals for Scotland's Sector

For RoslinCT, the USD 9.59 million award pairs commercial ambition with public sector backing as the company executes its digital expansion plan.

With Scottish Enterprise funding and Scottish Government endorsement in place, the company says the programme will create a more connected and data-driven manufacturing environment benefiting clients throughout the product lifecycle and, ultimately, patients awaiting innovative cell therapies, while reinforcing Scotland's international standing in cell and gene therapy manufacturing.